How to Get Jatenzo in Nevada

Why Jatenzo Exists and What It Does

Jatenzo became the first oral testosterone replacement therapy approved by the FDA in March 2019, ending decades in which men with hypogonadism had only injections, topical gels, or pellets as options. The active ingredient is testosterone undecanoate, formulated in a self-emulsifying lipid capsule that absorbs through the lymphatic system rather than the portal vein, bypassing first-pass liver metabolism that destroyed earlier oral testosterone products.

The key registration trial enrolled 166 hypogonadal men and demonstrated that 87% of patients achieved average testosterone concentrations within the normal range (300 to 1 to 100 ng/dL) at the 396 mg twice-daily dose after titration [1]. A separate cardiovascular safety study by Swerdloff et al. (2020) confirmed that Jatenzo did not produce clinically significant increases in ambulatory systolic blood pressure compared to topical testosterone, addressing an FDA concern that had delayed approval. The mean increase was 3.6 mmHg, a figure the FDA's Endocrinologic and Metabolic Drugs Advisory Committee weighed carefully before granting approval with a blood pressure monitoring requirement on the label [2].

For Nevada residents, this oral option removes the need for weekly injections or daily gel application. That convenience drives demand in a state where travel distances between cities can make frequent clinic visits impractical.

Telehealth Prescribing Rules in Nevada

Nevada law permits telehealth prescribing of controlled substances, including Schedule III drugs like Jatenzo. This is not a loophole. Nevada Revised Statutes Chapter 629 explicitly authorizes the practice when the prescriber holds an active Nevada medical license and establishes a provider-patient relationship via synchronous audio-video consultation.

A telehealth provider must be licensed by the Nevada State Board of Medical Examiners (for MDs and DOs) or the Nevada State Board of Nursing (for APRNs with full practice authority). Nevada grants APRNs independent prescriptive authority after a supervised period, so nurse practitioners can prescribe Jatenzo without physician co-signature once that threshold is met. Physician assistants prescribe under a collaborative agreement with a supervising physician.

The practical steps are straightforward. You schedule a video visit, present your lab work showing two separate morning total testosterone levels below 300 ng/dL, discuss symptoms, and receive a prescription electronically sent to your chosen pharmacy. The entire process can take under a week if labs are already in hand.

Lab Requirements Before You Get a Prescription

No responsible provider will prescribe Jatenzo without confirming biochemical hypogonadism. The Endocrine Society Clinical Practice Guideline (2018) requires two morning fasting total testosterone measurements, drawn between 7:00 and 10:00 AM when levels peak, on separate days [3].

Beyond testosterone, your provider will order baseline labs to screen for contraindications and establish monitoring benchmarks:

• Total and free testosterone (two separate morning draws)
• Complete blood count (CBC) with hematocrit, because testosterone therapy raises red blood cell mass, and a baseline hematocrit above 50% may contraindicate starting treatment
• Comprehensive metabolic panel including liver enzymes (AST, ALT)
• Lipid panel (LDL, HDL, triglycerides)
• PSA for men aged 40 and older, per American Urological Association screening guidance
• LH and FSH to help distinguish primary from secondary hypogonadism

If you are using a telehealth service, most will send you a lab order for Quest Diagnostics or Labcorp. Nevada has multiple draw sites in Las Vegas, Henderson, Reno, Sparks, and Carson City. Results typically post within 48 to 72 hours.

Once on therapy, the FDA-approved Jatenzo prescribing information requires checking testosterone levels after dose titration, then periodically. Hematocrit should be measured at 3 months, 6 months, and annually thereafter [4]. A hematocrit exceeding 54% requires dose reduction or temporary discontinuation.

Insurance Coverage and Prior Authorization in Nevada

Coverage varies sharply by payer. Here is the breakdown.

Nevada Medicaid does not cover Jatenzo. The Nevada Medicaid Preferred Drug List does not include oral testosterone undecanoate. Medicaid patients are directed toward generic injectable testosterone cypionate, which costs a fraction of Jatenzo's price.

Commercial insurance (Anthem, UnitedHealthcare, Aetna, Cigna, and others active in the Nevada exchange) generally covers Jatenzo as a non-preferred brand on formulary Tier 3 or Tier 4, subject to prior authorization. The documentation your provider must submit typically includes:

1. Two lab results confirming total testosterone below 300 ng/dL
2. A clinical diagnosis of male hypogonadism (ICD-10 code E29.1)
3. Documentation of medical necessity explaining why injectable or topical testosterone is not appropriate (allergy, skin reaction, adherence failure, or occupational transfer risk)
4. The specific dose prescribed (158 mg, 198 mg, 237 mg, or 396 mg twice daily)

Prior authorization decisions usually come back within 3 to 5 business days for commercial plans. Denials can be appealed, and Tolmar offers a patient assistance program that may reduce out-of-pocket costs for commercially insured patients to as low as $75 per month, depending on plan design.

Tricare covers testosterone replacement for diagnosed hypogonadism but may require step therapy through injectable testosterone first. Nevada has a significant military population near Nellis Air Force Base and the Fallon Naval Air Station, making this a common scenario.

Finding a Pharmacy That Stocks Jatenzo in Nevada

Jatenzo is not stocked at every retail pharmacy. It is a brand-name specialty drug with limited shelf demand. Large chains like CVS, Walgreens, and Walmart can order it, but expect a 2- to 5-day wait. Specialty pharmacies affiliated with your insurance plan will often ship it directly.

For faster access, ask your provider to send the prescription to a specialty pharmacy that already carries oral testosterone undecanoate. In the Las Vegas metro area, several independent pharmacies and compounding pharmacies maintain stock or can fill within 24 to 48 hours.

503A compounding pharmacies in Nevada are licensed by the Nevada State Board of Pharmacy and can compound oral testosterone undecanoate capsules from bulk powder under a patient-specific prescription. This option costs less than brand-name Jatenzo (often $150 to $300 per month versus $500+), but the compounded product is not FDA-approved and is not bioequivalent-tested against Jatenzo's proprietary lipid formulation. The lymphatic absorption that makes Jatenzo effective depends on its specific SEDDS (self-emulsifying drug delivery system) technology. A compounded capsule using a different vehicle may not deliver the same pharmacokinetics.

If you choose the compounding route, confirm that the pharmacy holds a current Nevada State Board of Pharmacy compounding license and follows USP <795> standards for non-sterile compounding.

Dosing and What to Expect in the First 90 Days

The starting dose for most patients is 237 mg taken twice daily with food. This is not optional. Food is required. The lipid-based absorption mechanism depends on dietary fat to trigger lymphatic uptake. Taking Jatenzo on an empty stomach reduces bioavailability by roughly 40%, according to the FDA prescribing information [4].

After 7 days on the starting dose, your provider orders a total testosterone level drawn 4 to 6 hours after the morning dose. Based on results:

• If the average serum testosterone concentration exceeds 1 to 050 ng/dL, the dose decreases to 198 mg twice daily
• If it falls between 300 and 1 to 050 ng/dL, the dose stays at 237 mg
• If it remains below 300 ng/dL, the dose increases to 396 mg twice daily
• A minimum dose of 158 mg twice daily is available for patients who overshoot on 198 mg

Symptom improvement follows a predictable timeline. Energy and mood changes often appear within 3 to 4 weeks. Improvements in sexual function, including libido and erectile quality, typically emerge by week 6 to 8. Body composition changes (increased lean mass, decreased fat mass) require 12 to 16 weeks of consistent therapy [5]. A meta-analysis by Corona et al. (2016) examining 59 randomized controlled trials (N=5,331) found that testosterone therapy produced a mean fat mass reduction of 1.6 kg and lean mass gain of 1.6 kg over 6 months [5].

Blood Pressure Monitoring: The Jatenzo-Specific Requirement

One requirement separates Jatenzo from every other testosterone formulation. The FDA mandated a REMS-like blood pressure monitoring program at the time of approval, though this was later relaxed. The concern came from pre-approval data showing a dose-dependent increase in systolic blood pressure.

In the Swerdloff et al. cardiovascular safety trial, the mean systolic blood pressure increase on Jatenzo was 3.6 mmHg versus 2.2 mmHg on topical testosterone [1]. While this difference was small, the FDA required prescribers to monitor blood pressure at baseline, after dose changes, and periodically during treatment. For telehealth patients in Nevada, this means owning a home blood pressure cuff and reporting readings to your provider. Automated cuffs from Omron or Withings cost $30 to $60 and are sufficient.

If systolic blood pressure rises above 140 mmHg or diastolic above 90 mmHg on two separate readings, the prescribing information recommends considering dose reduction or discontinuation [4]. Patients with pre-existing hypertension should achieve blood pressure control before starting Jatenzo.

Controlled Substance Regulations Specific to Nevada

Testosterone is a Schedule III controlled substance under both federal and Nevada law. Nevada imposes specific rules that affect how you receive and refill Jatenzo:

• Prescription validity: A Jatenzo prescription in Nevada is valid for 6 months from the date written, with up to 5 refills within that period.
• PDMP check: Nevada requires prescribers to query the Nevada Prescription Drug Monitoring Program (PDMP) before issuing a controlled substance prescription. This is automated in most EHR systems.
• No partial fills: Unlike Schedule II substances, Schedule III prescriptions can be partially filled at the pharmacy's discretion, which can help if cost is a barrier and you want to test tolerance on a 2-week supply first.
• Telehealth prescribing: The Ryan Haight Act requires at least one interaction with a DEA-registered provider before controlled substance prescribing. Nevada's telehealth laws satisfy this with a synchronous video visit. An audio-only phone call does not qualify.

Transferring a Jatenzo Prescription to Nevada

If you are relocating to Nevada from another state, your existing Jatenzo prescription can be transferred. Nevada Board of Pharmacy rules allow the receiving pharmacy to accept a transferred Schedule III prescription if refills remain. The transfer must occur pharmacy-to-pharmacy (you cannot carry a paper prescription across state lines for a controlled substance and expect it to be filled).

The simpler path: ask your new Nevada-based provider to write a fresh prescription. If you bring recent lab work (within the past 6 months) showing confirmed hypogonadism and stable testosterone levels on your current dose, most providers will continue the prescription without requiring repeat baseline labs, though they will want to verify hematocrit and blood pressure at a follow-up.

Who Can Prescribe Jatenzo in Nevada

Three categories of prescribers hold authority:

Medical Doctors (MD) and Doctors of Osteopathic Medicine (DO): Full prescriptive authority for all controlled substances, including Schedule III. Endocrinologists and urologists most commonly prescribe testosterone, but any licensed MD or DO can do so.

Advanced Practice Registered Nurses (APRN): Nevada grants APRNs full practice authority after completing a supervised period (typically 2 years or 2 to 000 hours). After that, APRNs prescribe Schedule III drugs independently. Many telehealth TRT platforms in Nevada use APRNs as primary prescribers.

Physician Assistants (PA): PAs prescribe under a collaborative agreement with a supervising physician. The agreement must explicitly include Schedule III controlled substances. The supervising physician does not need to be physically present.

All three provider types must hold an active DEA registration and a Nevada Controlled Substance Registration (CSR) issued by the Nevada Board of Pharmacy.